Dr. Cheryl Ho - Division of Medical ...

Dr. Cheryl Ho, MD

Claim this profile

BC Cancer

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
5 reported clinical trials
6 drugs studied

Area of expertise

1

Lung Cancer

Cheryl Ho, MD has run 2 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
EGFR positive
2

Non-Small Cell Lung Cancer

Cheryl Ho, MD has run 2 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
EGFR positive

Affiliated Hospitals

Image of trial facility.

BC Cancer

Image of trial facility.

BC Cancer - Vancouver Centre

Clinical Trials Cheryl Ho, MD is currently running

Image of trial facility.

Targeted Therapy

for Advanced Rare Cancers

This pilot clinical trial aims to assess the real world quality of life and survival of patients treated with targeted therapy that has preliminary evidence of efficacy in subjects with advanced rare cancers or cancer harbouring rare molecular aberrations. The treatment has been granted conditional or full approved by Health Canada (HC) as effective and safe. Due to the rarity of the cancer or molecular aberration the uncertainty level of the health technology assessment (HTA) by the pan Canadian Oncology Review (pCODR) was too high for consideration of funding or it was not submitted for consideration. Consequently, the goal of this study is to generate real world evidence to support HTA decision making throughout the life cycle of the product.

Recruiting

1 award

N/A

7 criteria

Image of trial facility.

CSF Analysis

for Non-Small Cell Lung Cancer

Leptomeningeal disease is malignant seeding of the leptomeninges and presents with a variety of symptoms frequently impacting quality of life. With improvement in treatment options, rates of leptomeningeal disease are increasing and currently found in up to 9% of EGFR mutant NSCLC. Systemic therapy may be more effective if it can target the correct molecular aberration. The molecular characterization of central nervous system disease may differ from disease outside of the central nervous system. The aim of this pilot trial is to evaluate for molecular differences between cerebral spinal fluid (CSF) and blood circulating tumor DNA (ctDNA) through the use of ddPCR and BC Cancer NGS panel molecular testing.

Recruiting

1 award

N/A

7 criteria

More about Cheryl Ho, MD

Clinical Trial Related

5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Cheryl Ho, MD has experience with

  • Osimertinib
  • Stereotactic Radiotherapy
  • FoundationOne Liquid CDx
  • Targeted Therapy
  • Lumbar Puncture And Phlebotomy
  • Pembrolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Cheryl Ho, MD specialize in?

Is Cheryl Ho, MD currently recruiting for clinical trials?

Are there any treatments that Cheryl Ho, MD has studied deeply?

What is the best way to schedule an appointment with Cheryl Ho, MD?

What is the office address of Cheryl Ho, MD?

Is there any support for travel costs?